European Journal of Clinical Pharmacology最新文献

筛选
英文 中文
Influence of genetic variants of imatinib on pharmacokinetics and recurrence-free survival in postoperative patients with gastrointestinal stromal tumor. 伊马替尼基因变异对胃肠道间质瘤术后患者药代动力学和无复发生存的影响。
IF 2.7 3区 医学
European Journal of Clinical Pharmacology Pub Date : 2025-10-06 DOI: 10.1007/s00228-025-03922-7
Luning Sun, Mingqing Xu, Qiang Zhang, Yi Liu, Qiongye Huang, Jianghao Xu, Fengyuan Li, Hao Xu, Yongqing Wang
{"title":"Influence of genetic variants of imatinib on pharmacokinetics and recurrence-free survival in postoperative patients with gastrointestinal stromal tumor.","authors":"Luning Sun, Mingqing Xu, Qiang Zhang, Yi Liu, Qiongye Huang, Jianghao Xu, Fengyuan Li, Hao Xu, Yongqing Wang","doi":"10.1007/s00228-025-03922-7","DOIUrl":"https://doi.org/10.1007/s00228-025-03922-7","url":null,"abstract":"<p><strong>Purpose: </strong>Imatinib is the first-line therapy for gastrointestinal stromal tumor (GIST), significantly enhancing patient prognosis. However, its clinical efficacy and safety are highly dependent on plasma concentration, which exhibits considerable interindividual variability. The purpose of this study is to determine the optimal monitoring time for imatinib concentration in postoperative patients with GIST, analyze single nucleotide polymorphisms affecting plasma concentration, and investigate their correlation with efficacy and adverse drug reactions (ADRs), offering valuable insights for personalized therapy.</p><p><strong>Methods: </strong>This study was conducted on 116 postoperative patients with GIST treated with imatinib in China between 2014 and 2018. Imatinib peak and trough concentrations (C<sub>max</sub> and C<sub>min</sub>) were measured in 608 samples using liquid chromatography-tandem mass spectrometry to determine the optimal monitoring time for steady-state concentration. DNA was extracted from 60 patients' peripheral blood to Genotype 22 single nucleotide polymorphisms in genes such as CYP3A4, CYP3A5, ABCB1, SLC22A1, and SLC22A5 (OCTN2). Therapeutic efficacy was evaluated based on recurrence-free survival (RFS), and ADRs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Statistical analyses were performed using SPSS 26.0, with p < 0.05 considered statistically significant.</p><p><strong>Results: </strong>The C<sub>max</sub> and C<sub>min</sub> of imatinib and its metabolite N-desmethyl imatinib reached their highest levels within the first month of treatment, and were stabilized by the third month. Genetic polymorphisms in ABCG2 (rs2231137), SLC22A1 (rs628031, rs3605065), and SLC22A5 (OCTN2) (rs2631372) were significantly associated with variations in imatinib C<sub>min</sub>. Genetic polymorphisms in CYP3A5 (rs776746), ABCG2 (rs2231137), and SLC22A1 (rs755828176) influenced imatinib C<sub>max</sub>. Patients carrying the CG and CC genotypes of SLC22A5 (OCTN2) (rs2631372) exhibited longer RFS and lower disease progression risk compared to those with the GG genotype (p < 0.05). Additionally, there was no significant correlation between the occurrence of ADRs and the studied genetic polymorphisms.</p><p><strong>Conclusions: </strong>Imatinib plasma concentration was stabilized by the third month in postoperative patients with GIST. Genetic polymorphisms in ABCG2, SLC22A1, and SLC22A5 (OCTN2) were associated with imatinib plasma concentration, while SLC22A5 (OCTN2) also influenced recurrence rates. These results provide a reference for personalized therapy and concentration monitoring.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and safety of concomitant use of direct oral anticoagulants and antiarrhythmic drugs: a systematic review of observational studies. 直接口服抗凝剂和抗心律失常药物同时使用的有效性和安全性:观察性研究的系统回顾。
IF 2.7 3区 医学
European Journal of Clinical Pharmacology Pub Date : 2025-10-01 Epub Date: 2025-07-16 DOI: 10.1007/s00228-025-03883-x
Fabian Maximilian Meinert, Jenny Dimakos, Thomas Günther Riemer, Antonios Douros
{"title":"Effectiveness and safety of concomitant use of direct oral anticoagulants and antiarrhythmic drugs: a systematic review of observational studies.","authors":"Fabian Maximilian Meinert, Jenny Dimakos, Thomas Günther Riemer, Antonios Douros","doi":"10.1007/s00228-025-03883-x","DOIUrl":"10.1007/s00228-025-03883-x","url":null,"abstract":"<p><strong>Introduction: </strong>Concomitant use of antiarrhythmic drugs (AAs) may affect the effectiveness and safety of direct oral anticoagulants (DOACs) through pharmacokinetic interactions and other factors. Our systematic review aimed to provide an in-depth methodological assessment and synthesis of the available real-world evidence in the area.</p><p><strong>Methods: </strong>We systematically searched MEDLINE/PubMed and EMBASE from January 2011 to October 2024 for observational studies assessing the effectiveness (risk of stroke) and safety (risk of major bleeding) associated with concomitant use of DOACs and AAs. We assessed the risk of bias using the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool.</p><p><strong>Results: </strong>We identified 17 relevant studies including overall 2,613,693 patients. For stroke, all six studies showed no increased risk associated with concomitant use of DOACs and AAs. For major bleeding, seven studies showed an increased risk associated with concomitant use of DOACs and AAs (up to 187%), four studies showed heterogeneous results depending on the specific AA, and six studies showed no increased risk. When considering only higher-quality studies (n = 6), there was no association with the risk of stroke (n = 3). There were associations with an increased risk of major bleeding for concomitant use of DOACs and diltiazem (n = 2) or verapamil (n = 1), while findings for concomitant use of DOACs and amiodarone were inconsistent (n = 3).</p><p><strong>Conclusions: </strong>Based on the synthesis of higher-quality real-world evidence, concomitant use of AAs does not seem to impact the effectiveness of DOACs. Findings on safety possibly depend on the specific AA, with diltiazem showing the highest risk.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1409-1419"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12443910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
External validation of population pharmacokinetic models of oxcarbazepine active metabolite in Chinese children with epilepsy. 中国癫痫患儿奥卡西平活性代谢物群体药动学模型的外部验证。
IF 2.7 3区 医学
European Journal of Clinical Pharmacology Pub Date : 2025-10-01 Epub Date: 2025-07-24 DOI: 10.1007/s00228-025-03875-x
Ruoyun Wu, Xintian Li, Yujie Wu, Zhigang Zhao, Weixing Feng, Shenghui Mei
{"title":"External validation of population pharmacokinetic models of oxcarbazepine active metabolite in Chinese children with epilepsy.","authors":"Ruoyun Wu, Xintian Li, Yujie Wu, Zhigang Zhao, Weixing Feng, Shenghui Mei","doi":"10.1007/s00228-025-03875-x","DOIUrl":"10.1007/s00228-025-03875-x","url":null,"abstract":"<p><strong>Objective: </strong>To assess the predictive performance of published population pharmacokinetic models of the oxcarbazepine (OXC) active metabolite, 10, 11-dihydro-10-monohydroxycarbazepine (MHD), using external data sets in Chinese children with epilepsy.</p><p><strong>Method: </strong>A total of 231 concentrations from 185 Chinese children with epilepsy were used for external validation. PubMed, Embase, and Web of Science were searched for published PPK models of OXC active metabolite MHD in children. Seven models were searched and labeled A to G based on the year of publication. Prediction error, visual predictive check, and normal prediction distribution error tests were employed to assess the model's extrapolation performance. The Bayesian prediction method was applied to ascertain the influence of prior concentrations on the model's predictive performance.</p><p><strong>Result: </strong>A total of seven MHD PPK models were retrieved. Models A, D, E, and G exhibited good predictive performance in prediction-based diagnostics and visual predictive checks. The normalized predictive distribution error test shows that none of the models is suitable to describe our data. Bayesian prediction significantly improved the prediction performance of all the models with one prior observation.</p><p><strong>Conclusion: </strong>The published MHD PPK models showed extensive variation in predictive performance when extrapolated in Chinese children with epilepsy. Bayesian forecasting substantially improved the predictive performance of the model and might facilitate the customization of OXC dosing.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1439-1449"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Possible increased risks of cholecystitis in patients with idiopathic pulmonary fibrosis treated with nintedanib. 尼达尼布治疗特发性肺纤维化患者胆囊炎的风险可能增加。
IF 2.7 3区 医学
European Journal of Clinical Pharmacology Pub Date : 2025-10-01 Epub Date: 2025-07-23 DOI: 10.1007/s00228-025-03867-x
Catherine Kiani, Alexandre Bleinc, Theodora Bejan-Angoulvant, Marion Teulier, Sylvain Marchand-Adam
{"title":"Possible increased risks of cholecystitis in patients with idiopathic pulmonary fibrosis treated with nintedanib.","authors":"Catherine Kiani, Alexandre Bleinc, Theodora Bejan-Angoulvant, Marion Teulier, Sylvain Marchand-Adam","doi":"10.1007/s00228-025-03867-x","DOIUrl":"10.1007/s00228-025-03867-x","url":null,"abstract":"","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1533-1535"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12443869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study on disproportionality in the detection of potential signals between quetiapine and diabetic ketoacidosis. 喹硫平与糖尿病酮症酸中毒电位信号检测的歧化性研究。
IF 2.7 3区 医学
European Journal of Clinical Pharmacology Pub Date : 2025-10-01 Epub Date: 2025-07-28 DOI: 10.1007/s00228-025-03895-7
Haiya Liang, Dandan Mao, Yan Zhao, Rongjing Zhou
{"title":"Study on disproportionality in the detection of potential signals between quetiapine and diabetic ketoacidosis.","authors":"Haiya Liang, Dandan Mao, Yan Zhao, Rongjing Zhou","doi":"10.1007/s00228-025-03895-7","DOIUrl":"10.1007/s00228-025-03895-7","url":null,"abstract":"<p><strong>Purpose: </strong>Quetiapine is an atypical second-generation antipsychotic. Diabetic ketoacidosis (DKA) is an acute metabolic complication, most commonly encountered in type 1 diabetes, and it can be life-threatening if not treated promptly. This study aimed to assess quetiapine-associated DKA using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.</p><p><strong>Methods: </strong>We performed a retrospective investigation on the FAERS from the first quarter of 2004 to the second quarter of 2024 using the reporting odds ratio (ROR) and proportional reporting ratio (PRR) from the disproportionality analysis. According to the Medical Dictionary for Regulatory Activities (MedDRA) 26.1, preferred terms (PTs) of reports on adverse drug reactions (ADRs) were classified using System Organ Classification (SOC), and filtered based on hyperglycemia and new-onset diabetes mellitus in the Standardized MedDRA Query (SMQ).</p><p><strong>Results: </strong>We collected 65,536 ADR reports with quetiapine as the primary suspected drug, including 27 system organ classifications. There were 3,046 cases related to DKA, predominantly from the United States, with a slightly higher proportion of females (51.31%) than males (45.63%). The most common severe ADR outcome (539 cases, 17.70%) was hospitalization-initial or prolonged, followed by death (333 cases, 10.93%). Additionally, compared to the other three second-generation antipsychotics (clozapine, olanzapine, and risperidone), quetiapine exhibited a stronger association with DKA (ROR = 31.05, ROR025 = 29.87).</p><p><strong>Conclusion: </strong>Quetiapine could be associated with DKA; therefore, physicians should be aware of this potentially fatal adverse event. Studies are needed to investigate the matter further.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1473-1479"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benchmarking non-inferiority design and analysis through the Z-score. 通过z分数对标非劣效性设计和分析。
IF 2.7 3区 医学
European Journal of Clinical Pharmacology Pub Date : 2025-10-01 Epub Date: 2025-07-17 DOI: 10.1007/s00228-025-03877-9
Jin Wang
{"title":"Benchmarking non-inferiority design and analysis through the Z-score.","authors":"Jin Wang","doi":"10.1007/s00228-025-03877-9","DOIUrl":"10.1007/s00228-025-03877-9","url":null,"abstract":"<p><strong>Purpose: </strong>Non-inferiority (NI) design and analyses are frequently employed to provide alternative therapy options to patients, ensuring these therapies are not significantly worse in terms of safety and effectiveness compared to the standard therapy. However, unlike superiority analysis, non-inferiority analysis faces the inherent challenge of a potentially irrelevant NI margin. It is not uncommon for the observed control performance to differ significantly from the assumed one, which can render the NI margin irrelevant. The purpose of this paper is to utilize Z-score to investigate this issue.</p><p><strong>Methods: </strong>This paper proposes using the Z-score to evaluate the NI design and connect the NI design and analysis. This approach provides a benchmark tool that even when actual outcomes differ significantly from assumptions, the NI margin can be moderated to balance clinical relevance and statistical practicality.</p><p><strong>Results: </strong>Illustrative calibrations and case studies demonstrate the feasibility of this approach, facilitating the transition from NI design to analysis.</p><p><strong>Conclusion: </strong>The Z-score can be used to assess the quality of the NI design and serve as a bridge between NI design and analysis.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1421-1427"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenetics and pharmacometabolomics predictors of clozapine and norclozapine pharmacokinetic exposure in healthy volunteers. 健康志愿者氯氮平和去氯氮平药代动力学暴露的药物遗传学和药物代谢组学预测因子。
IF 2.7 3区 医学
European Journal of Clinical Pharmacology Pub Date : 2025-10-01 Epub Date: 2025-07-22 DOI: 10.1007/s00228-025-03884-w
Orwa Albitar, Mohd Rahimi Muda, Siti Maisharah Sheikh Ghadzi, Dzul Azri Mohamed Noor, Baharudin Ibrahim, Chin-Hoe Teh, Mohammed Ahmed Akkaif, Fatimatuzzahra' Abd Aziz
{"title":"Pharmacogenetics and pharmacometabolomics predictors of clozapine and norclozapine pharmacokinetic exposure in healthy volunteers.","authors":"Orwa Albitar, Mohd Rahimi Muda, Siti Maisharah Sheikh Ghadzi, Dzul Azri Mohamed Noor, Baharudin Ibrahim, Chin-Hoe Teh, Mohammed Ahmed Akkaif, Fatimatuzzahra' Abd Aziz","doi":"10.1007/s00228-025-03884-w","DOIUrl":"10.1007/s00228-025-03884-w","url":null,"abstract":"<p><strong>Purpose: </strong>Clozapine is the only effective medication for unresponsive schizophrenia. However, it has a complicated dose-concentration relationship. The present study aimed to investigate the role of some genetic polymorphisms and metabolic profiles in addressing the variability in clozapine and norclozapine concentrations.</p><p><strong>Methods: </strong>A single dose of 12.5 mg clozapine was administered to 33 healthy volunteers, from whom 270 samples were collected at 30 min, 1, 2, 3, 5, and 8 h. The concentrations of clozapine and norclozapine were determined using HPLC-UV. CYP1A2 -163 C>A, ABCB1 3435 C>T, and ABCB1 2677 G>T genetic polymorphisms were investigated using allele-specific polymerase chain reaction and restriction fragment length polymorphism, and the metabolic profiles were identified using proton nuclear magnetic resonance (<sup>1</sup>H NMR).</p><p><strong>Results: </strong>Clozapine concentrations and area under the curve (AUC) were higher, and the clearance was 38.3% (95% confidence intervals (95% CI), 4.5-72.2%) lower in the CYP1A2 -163 AA genotype, while clozapine initial concentrations were lower in the ABCB1 2677 GG genotype. In a multiple regression analysis, glucose (p-value, 0.009) was significantly associated with the norclozapine to clozapine AUC (N:C) ratio.</p><p><strong>Conclusions: </strong>Variabilities in clozapine pharmacokinetics were accounted for using genetic polymorphisms and metabolic profiles. Clozapine concentrations in CYP1A2 -163 C>A polymorphism should be cautiously interpreted considering the smoking status. Altered glucose levels, besides being an adverse effect of clozapine, may also be indirectly associated with variability in CYP1A2 activity as indicated by the N:C ratio to be confirmed in larger and controlled trials.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1429-1438"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness of abortive and preventative treatments in patients with migraine: a systematic review. 流产和预防性治疗在偏头痛患者中的成本效益:一项系统综述。
IF 2.7 3区 医学
European Journal of Clinical Pharmacology Pub Date : 2025-10-01 Epub Date: 2025-07-15 DOI: 10.1007/s00228-025-03881-z
Arefe Rashidi, Mohammadreza Keramati, Hadi Esmaily, Maryam Talebi, Ghader Mohammadnezhad
{"title":"Cost-effectiveness of abortive and preventative treatments in patients with migraine: a systematic review.","authors":"Arefe Rashidi, Mohammadreza Keramati, Hadi Esmaily, Maryam Talebi, Ghader Mohammadnezhad","doi":"10.1007/s00228-025-03881-z","DOIUrl":"10.1007/s00228-025-03881-z","url":null,"abstract":"<p><strong>Background: </strong>Migraine imposes significant personal, societal, and economic burdens globally. Both abortive and preventative medications have evolved, yet their economic implications require further exploration, particularly for high-cost novel therapies such as calcitonin gene-related peptide (CGRP) inhibitors. This systematic review evaluates the cost-effectiveness of migraine interventions, focusing on both abortive and preventive interventions across diverse healthcare settings.</p><p><strong>Methods: </strong>A systematic review was conducted to evaluate economic evaluations of migraine treatments published between 2014 and 2024. Inclusion criteria comprised full economic evaluations reporting incremental cost-effectiveness ratios (ICERs) and quality-adjusted life years (QALYs). Data extracted included country settings, perspectives, interventions compared, real-world data sources or economic models, and key outcomes.</p><p><strong>Results: </strong>Of the 2172 unique records screened, 20 eligible peer-reviewed studies were included. Recent studies have focused on CGRP inhibitors, especially erenumab. However, BTX, anticonvulsants, surgery, simple analgesics, triptans, medical devices, and direct-site anesthetic/glucocorticoid injections are still discussed in some contexts. CGRP inhibitor monoclonal antibodies demonstrated ICERs ranging from 50,000 to 250,000 USD/QALY in high-income countries but often exceeded willingness-to-pay (WTP) thresholds in lower-resource settings. Preventive modalities like BTX were cost-effective for chronic migraine, with ICERs of 30,000-70,000 USD/QALY. Sensitivity analyses revealed that drug costs, adherence, and discount rates significantly influenced results.</p><p><strong>Conclusion: </strong>Economic evaluations underscore the clinical benefits of novel migraine therapies but reveal price challenges, particularly in resource-limited settings. Biosimilar adoption and head-to-head cost comparisons are essential to improving access. Tailoring migraine management strategies to regional economic contexts remains critical to achieving sustainable and equitable care.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1381-1399"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effects of trazodone exposure during pregnancy on fetal outcomes: a systematic review. 妊娠期间曲唑酮暴露对胎儿结局的影响:一项系统综述。
IF 2.7 3区 医学
European Journal of Clinical Pharmacology Pub Date : 2025-10-01 Epub Date: 2025-07-21 DOI: 10.1007/s00228-025-03880-0
Britney Glasgow-Osment, Farah Wahib, Shama Kassam, Madeleine Zanin, Facundo Garcia-Bournissen
{"title":"The effects of trazodone exposure during pregnancy on fetal outcomes: a systematic review.","authors":"Britney Glasgow-Osment, Farah Wahib, Shama Kassam, Madeleine Zanin, Facundo Garcia-Bournissen","doi":"10.1007/s00228-025-03880-0","DOIUrl":"10.1007/s00228-025-03880-0","url":null,"abstract":"<p><strong>Purpose: </strong>Trazodone, a medication primarily used for anxiety and insomnia, is increasingly prescribed during pregnancy despite limited safety data. This systematic review aims to assess the effects of trazodone exposure during pregnancy on fetal outcomes.</p><p><strong>Methods: </strong>A search was conducted using MEDLINE and Embase databases from the year 2000 to present. Studies were limited to those involving human subjects, published in English, and investigating trazodone exposure during pregnancy. Keywords included \"pregnan*,\" \"trazodone,\" \"malformation*,\" and \"birth outcomes.\" Four reviewers independently extracted data from the selected records. Risk of bias was assessed using the Newcastle-Ottawa Scale. Data synthesis involved a qualitative analysis to summarize and interpret the findings, identifying patterns across the studies.</p><p><strong>Results: </strong>Fourteen studies met the inclusion criteria. The main outcome measures included fetal and pregnancy outcomes such as congenital malformations, developmental outcomes, poor neonatal adaptation syndrome (PNAS), persistent pulmonary hypertension of the newborn (PPHN), congenital heart defects, gestational age, birth weight, stillbirth, preterm birth, spontaneous and therapeutic abortion, and pre-eclampsia.</p><p><strong>Conclusion: </strong>The review found no consistent evidence linking trazodone use during pregnancy to increased risks of congenital malformations, stillbirths, or low birth weight. However, some studies suggested a possible association with an increased risk of spontaneous and therapeutic abortions. Given the limited and varied data, further research with larger, well-controlled studies are needed to establish the safety profile of trazodone during pregnancy. Overall, clarifying the specific risks and benefits of trazodone use in pregnancy will better guide clinical decision-making and improve maternal-fetal health outcomes.</p><p><strong>Trial registration: </strong>PROSPERO number: CRD42024503611.</p>","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1401-1408"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From adoption to impact: linking prescribing tools to clinical outcomes-authors' response. 从采用到影响:将处方工具与临床结果联系起来——作者的回应。
IF 2.7 3区 医学
European Journal of Clinical Pharmacology Pub Date : 2025-10-01 Epub Date: 2025-07-24 DOI: 10.1007/s00228-025-03888-6
Monia Donati, Carlotta Lunghi, Giulia Grillini, Marco Domenicali, Maria Lia Lunardelli, Veronica Pasini, Susy Milandri, Monica Mussoni, Fabio Pieraccini, Elisa Sangiorgi, Emanuel Raschi, Valentina Colonnello, Elisabetta Poluzzi
{"title":"From adoption to impact: linking prescribing tools to clinical outcomes-authors' response.","authors":"Monia Donati, Carlotta Lunghi, Giulia Grillini, Marco Domenicali, Maria Lia Lunardelli, Veronica Pasini, Susy Milandri, Monica Mussoni, Fabio Pieraccini, Elisa Sangiorgi, Emanuel Raschi, Valentina Colonnello, Elisabetta Poluzzi","doi":"10.1007/s00228-025-03888-6","DOIUrl":"10.1007/s00228-025-03888-6","url":null,"abstract":"","PeriodicalId":11857,"journal":{"name":"European Journal of Clinical Pharmacology","volume":" ","pages":"1537-1538"},"PeriodicalIF":2.7,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信